К содержанию
Dr. Tara EinullaevaMedical oncologist

Treatment 10 min

Small cell lung cancer: how limited-stage and extensive-stage disease is treated

Small cell lung cancer: how it differs from other lung cancers, how it is staged, how it is treated (chemoradiotherapy, immunotherapy, second line) and what to discuss with your doctor.

Written and medically reviewed by

Dr. Tara Einullaeva

Medical oncologist, 9 years in practice. Credentials · reviewed 31 October 2026

Small cell lung cancer (SCLC) is a distinct type of cancer that differs from the more common non-small cell lung cancer. It grows quickly and spreads early, but it is usually sensitive to chemotherapy and radiotherapy. That is why treatment starts without delay, and the choice of regimen depends first of all on whether the disease is limited stage or extensive stage.

In this article I explain what these terms mean, what the stages of treatment are, why a brain MRI matters, what immunotherapy does in SCLC and what to do if the disease returns.

How small cell differs from non-small cell lung cancer

Small cell cancer accounts for a minority of lung tumours, but it behaves in its own way.

  • It grows fast. Tumour doubling time is short, and symptoms often appear within weeks rather than months.
  • It spreads early. By the time of diagnosis there are often metastases in lymph nodes, liver, adrenal glands, bones and brain.
  • It responds well to first treatment. Chemotherapy and radiotherapy work quickly, but in many patients the disease returns.
  • It is closely linked to smoking. But it also occurs in people who never smoked, so the diagnosis should not be taken as a reason for guilt.
  • Targetable mutations are usually absent. Unlike non-small cell cancer, EGFR, ALK and similar targets do not apply here, so the treatment backbone is different: chemotherapy plus radiotherapy and immunotherapy. More about mutations in the other lung cancer type: mutations in lung cancer.

How the diagnosis is made and what needs to be examined

The diagnosis is confirmed by biopsy: bronchoscopy, transthoracic needle biopsy or biopsy of a lymph node. The pathologist describes small cells with a high division rate. Immunohistochemistry (synaptophysin, chromogranin, CD56, TTF-1) and Ki-67, which is usually very high in SCLC, are often added. If the report raises doubts (for example, separating small cell from neuroendocrine or non-small cell cancer), a pathology slide review makes sense.

To determine the stage you usually need:

  • CT of the chest and abdomen with contrast;
  • brain MRI with contrast: in SCLC it is essential even without symptoms, because brain metastases often start silently;
  • PET-CT: especially important in limited stage to avoid missing distant lesions;
  • blood tests: complete blood count and chemistry, LDH, sodium, liver and kidney function.

Low sodium may be a sign of a paraneoplastic syndrome (excess secretion of antidiuretic hormone), and this too needs to be known before chemotherapy starts. More on how to read the stage letters: TNM.

Limited and extensive stage

For SCLC a two-step classification has long been used, and it is still applied alongside TNM.

Stage What it means What it determines
Limited The tumour and involved lymph nodes can be covered by one radiotherapy field in the chest, no distant metastases Curative-intent chemoradiotherapy is possible
Extensive Metastases in other organs, malignant pleural effusion, or lesions that cannot be covered by one radiotherapy field The backbone of treatment is drug therapy

A minority of patients present with limited stage. But even in extensive stage, treatment gives a real effect and helps control symptoms.

Treatment of limited stage

In limited stage the goal is cure. The standard approach has several steps.

  1. Platinum plus etoposide chemotherapy (cisplatin or carboplatin + etoposide), usually 4 cycles.
  2. Chest radiotherapy given at the same time as chemotherapy, ideally started early, with the first or second cycle. This combination is called chemoradiotherapy. Radiotherapy is given either twice a day in smaller doses or once a day. The radiation oncologist chooses the schedule.
  3. Maintenance immunotherapy. If the disease has not progressed after chemoradiotherapy, durvalumab for up to two years is discussed based on the ADRIATIC trial. Availability and indications depend on the country and on registration, so check this with your doctor.
  4. Prophylactic cranial irradiation or MRI surveillance. See the separate section below.

For a very small group of patients with the earliest stage (a single focus without lymph node involvement), surgery followed by chemotherapy is discussed. This is an exception and a tumour board makes the decision.

Treatment of extensive stage

Here the goal is to control the disease, prolong life and preserve its quality. The main approach is as follows.

  • Platinum plus etoposide chemotherapy combined with immunotherapy (atezolizumab or durvalumab, depending on the regimen and availability). Chemotherapy is usually given for 4 cycles, after which immunotherapy continues as maintenance.
  • Response assessment by CT after 2–3 cycles. If the response is good, the regimen continues.
  • Chest radiotherapy is sometimes added after a response to drug treatment if residual lesions remain in the lung. This is discussed individually.
  • Irradiation of metastases that cause symptoms: in bones, brain, or when the superior vena cava or a bronchus is compressed.

Immunotherapy has its own side effects: inflammation in the bowel, lungs, liver, thyroid and other organs. You need to know how to recognise them: immunotherapy side effects and when to call your doctor: symptoms during treatment.

Brain metastases and prophylactic irradiation

SCLC often metastasises to the brain, sometimes already at diagnosis. Therefore:

  • head MRI is done before treatment and then regularly;
  • if metastases are found, brain radiotherapy or stereotactic radiosurgery is usually given while drug treatment continues;
  • after a response to the main treatment, prophylactic cranial irradiation (PCI), which lowers the risk of brain metastases, or MRI surveillance every few months as an alternative is discussed.

Whole-brain irradiation may affect memory and attention, especially in older people and in those who already have cognitive problems. So the choice between PCI and surveillance depends on age, condition, MRI results and your decision. Ask your doctor to go through the pros and cons for you specifically.

What to do if the disease returns

Relapse in SCLC is common. The approach depends on the treatment-free interval.

Situation Typical approach
Relapse 3 months or more after platinum Repeating a platinum regimen or other drugs can be considered
Relapse earlier than 3 months (refractory) Other drugs or clinical trials are needed
Relapse in one or two lesions Local treatment such as radiotherapy is sometimes discussed

Second-line options include topotecan, lurbinectedin (in countries where it is registered), and for relapse after platinum in some countries tarlatamab (a drug against the DLL3 target). The choice depends on availability, condition, organ function and the earlier response. If standard options are exhausted, it makes sense to look at clinical trials. If the disease grew on treatment, read what this means: progression on treatment.

How long treatment lasts and what about side effects

Chemotherapy usually takes about 3–4 months. Chest radiotherapy runs for several weeks. Maintenance immunotherapy, if indicated, can continue for up to two years.

On platinum plus etoposide chemotherapy the most common problems are:

On chest radiotherapy there may be pain and difficulty swallowing from oesophageal inflammation, cough and shortness of breath, and several months later radiation pneumonitis. If shortness of breath, cough and fever appear after radiotherapy, tell your doctor immediately.

Smoking and supportive care

If you smoke, it is better to stop: it improves treatment tolerance, lowers the risk of complications after radiotherapy and helps breathing. Ask for help: nicotine replacement and support from your doctor are not condemnation but part of treatment.

Alongside the main treatment, palliative care matters: control of breathlessness, cough, pain, nutrition and mood. It is not a last stage but support along the whole way (more: palliative chemotherapy and pain relief in cancer).

What to ask your doctor

  • What is my stage by the limited or extensive classification and by TNM? What did the brain MRI and PET-CT show?
  • Will I have chest radiotherapy? When does it start and on what schedule?
  • Is immunotherapy suitable for me and for how long would I take it?
  • What are we discussing: prophylactic brain irradiation or MRI surveillance?
  • What do we do if the disease returns, and what options will I have?
  • Are there clinical trials I could join?
  • How do I cope with smoking and nutrition during treatment?

When to seek urgent help

Contact your doctor the same day or call an ambulance if:

  • temperature is 38 °C or above, or you have chills (especially a few days after chemotherapy);
  • shortness of breath, severe cough, chest pain, coughing up blood;
  • swelling of the face and neck, difficulty breathing, swollen neck veins (signs of superior vena cava compression);
  • sudden weakness of an arm or leg, speech problems, seizures, severe headache, confusion;
  • you cannot swallow liquid, or have uncontrollable vomiting or diarrhoea.

Can I get a second opinion

In small cell lung cancer time matters, so a second opinion is best obtained quickly and in parallel with treatment, not instead of it. It is especially useful if:

  • you were offered a regimen without chest radiotherapy in limited stage;
  • no brain MRI was done;
  • a change of line is being discussed at relapse;
  • you are unsure about the histology or the stage.

For the review you need the histology report, CT and MRI with reports (ideally the images themselves on a disc), discharge summaries and treatment protocols. More on what to collect: how to prepare for an oncology consultation and documents for a second opinion. If you need help with the review, book a consultation: I study the documents in advance and send a written summary after the call.

You can find general information on the approach to lung cancer on the page lung cancer.

Sources

  1. Small Cell Lung Cancer Treatment (PDQ) — National Cancer Institute
  2. ESMO Clinical Practice Guidelines — ESMO
  3. Practical guidelines for drug treatment of malignant tumours — RUSSCO (Russian Society of Clinical Oncology)
  4. Clinical guidelines (Russia) — Russian Ministry of Health

Frequently asked questions

This article is for information only and does not replace a consultation with your treating doctor. Decisions about tests and treatment are made by the doctor who looks after you.